MRNA biomarker detection in liquid-based cytology: A new approach in the prevention of cervical cancer

Modern Pathology

Volumn 28, Issue 2, 2015, Pages 312-320

  Del Pino, Marta ^a   Svanholm Barrie, Cecilia ^b   Torné, Aureli ^a   Marimon, Lorena ^a   Gaber, Jina ^b   Sagasta, Amaia ^a   Persing, David H ^c   Ordi, Jaume ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Cepheid   (Sweden)

^c CEPHEID   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; BIRC5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; GELATINASE B; INHIBITOR OF APOPTOSIS PROTEIN; MCM5 PROTEIN, HUMAN; MKI67IP PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER; VIRUS DNA;

ARTICLE; BIRC5 GENE; CDKN2A GENE; COLPOSCOPY; CURETTAGE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MCM5 GENE; MKI67 GENE; MMP9 GENE; ONCOGENE; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; TOP2A GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; BIOSYNTHESIS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; EARLY DIAGNOSIS; GENETICS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR;

ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; DNA TOPOISOMERASES, TYPE II; DNA, VIRAL; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 9; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84921966712     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.106     Document Type: Article

References (32)

1. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689.
2. Kyndi M, Frederiksen K, Kruger KS. Cervical cancer incidence in Denmark over six decades (1943-2002). Acta Obstet Gynecol Scand 2006;85:106-111.
3. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757-1764.
4. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597.
5. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-211.
6. Darragh TM, Colgan TJ, Thomas CJ, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32:76-115.
7. Barbosa LC, da Silva I, Correa JC, Ribalta JC. Survivin and telomerase expression in the uterine cervix of women with human papillomavirus-induced lesions. Int J Gynecol Cancer 2011;21:15-21.
8. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005;331: 269-291.
9. Williams GH, Romanowski P, Morris L, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998;95:14932-14937.
10. del Pino M, Garcia S, Fuste V, et al. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009;201:488-7.
11. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
12. Ordi J, Alonso I, Torne A, et al. Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol 2005;99: 313-319.
13. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010;133:395-406.
14. Casals G, Ordi J, Creus M, et al. Expression pattern of osteopontin and alphavbeta3 integrin during the implantation window in infertile patients with early stages of endometriosis. Hum Reprod 2012;27:805-813.
15. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
16. Ordi J, Garcia S, del Pino M, et al. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol 2009;28: 90-97.
17. Hariri J, Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007;26:223-228.
18. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. J Natl Cancer Inst 2013;105:1550-1557.
19. Ordi J, Sagasta A, Munmany M, et al. Usefulness of p16/Ki67 immunostaining in the triage of women referred to Colposcopy. Cancer Cytopathol 2014;122: 227-235.
20. Boulet GA, Horvath CA, Depuydt CE, Bogers JJ. Biomarkers in cervical screening: quantitative reverse transcriptase PCR analysis of P16INK4a expression. Eur J Cancer Prev 2010;19:35-41.
21. Branca M, Giorgi C, Santini D, et al. Survivin as a marker of cervical intraepithelial neoplasia and highrisk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-121.
22. Gupta N, Srinivasan R, Rajwanshi A. Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 2010;38:618-623.
23. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006;108: 324-330.
24. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35: 210-220.
25. Cuschieri KS, Beattie G, Hassan S, et al. Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods 2005;124:211-215.
26. Horvath CA, Boulet G, Sahebali S, et al. Effects of fixation on RNA integrity in a liquid-based cervical cytology setting. J Clin Pathol 2008;61:132-137.
27. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 2006;137:58-62.
28. Habis AH, Vernon SD, Lee DR, et al. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev 2004;13:492-496.
29. Martin CM, Astbury K, McEvoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol 2009;511:333-359.
30. Bourmenskaya O, Shubina E, Trofimov D, et al. Host gene expression profiling of cervical smear is eligible for cancer risk evaluation. J Clin Pathol 2013;66:282-285.
31. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5: 447-452.
32. Li F. Survivin study: what is the next wave? J Cell Physiol 2003;197:8-29.